【摘要】 目的观察依达拉奉联合奥扎格雷钠治疗急性进展性脑梗死(PCI)临床的疗效。方法选择诊断明确并且发病在48 h内的PCI患者126例,随机分成治疗组(64例)和对照组(62例)。治疗组给予奥扎格雷钠和依达拉奉联合治疗,连续14 d;对照组仅用同剂量、同疗程的奥扎格雷钠。两组其他对症治疗均相同,连续治疗14 d。2组均未见明显不良反应。2组患者治疗前及治疗后7 d及14 d时均进行临床神经功能缺损程度评分及临床疗效评定。结果治疗组总有效率(92.2%)显著高于对照组(79.0%),差异有统计学意义(P<0.05)。治疗组在治疗后7 d时与对照组比较差异有统计学意义(P<0.05),两组治疗无明显不良反应。结论奥扎格雷钠和依达拉奉联合治疗PCI患者疗效及安全性好。更多还原

【Abstract】 Objective To observe the combined Ozagrel edaravone treatment of acute progressive cerebral infarction(PCI) clinical efficacy.Methods Diagnosis of a clear and incidence in the PCI within 48h in patients with 126 cases were randomly divided into treatment group(64 cases) and control group(62 cases).Group was treated with sodium and Edaravone Ozagrel combination therapy for 14 consecutive days;the control group only with the dose,with the course of Ozagrel.Symptomatic treatment of other groups are the same,continuous treatment for 14 days.Two groups were no obvious adverse reactions.Two patients before treatment and after treatment 7 d and 14 d,when both the degree of clinical neurological deficit score and the clinical efficacy evaluation.Results The total effective rate(92.2%) was significantly higher(79.0%),the difference was statistically significant(P <0.05).The treatment group 7 d after treatment,compared with the control group,the difference was statistically significant(P<0.05),the treatment groups had no significant adverse reactions.Conclusion Ozagrel and the combination therapy of edaravone efficacy and safety of PCI in patients with good.更多还原